Quantcast

CorMedix Inc. to Present at the 20th Annual B. Riley FBR Institutional Investor Conference

By GlobeNewswire,  May 16, 2019, 08:45:00 AM EDT


BERKELEY HEIGHTS, N.J., May 16, 2019 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that management will present a corporate overview at the 20th Annual B. Riley FBR Institutional Investor Conference, being held May 22-23 at the Beverly Hilton Hotel in Beverly Hills, California.

20th Annual B. Riley FBR Institutional Investor Conference

Date:    Wednesday, May 22nd 
Time: 2:00pm Eastern/11:00am Pacific Time
Webcast:    http://www.wsw.com/webcast/brileyfbr3/crmd/

About CorMedix

CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company is focused on developing its lead product Neutrolin®, a novel, non-antibiotic antimicrobial solution designed to prevent costly and dangerous bloodstream infections associated with the use of central venous catheters, currently in Phase 3 development for patients undergoing chronic hemodialysis. Such infections have significant treatment costs and lead to increased morbidity and mortality. Neutrolin has FDA Fast Track status and is designated as a Qualified Infectious Disease Product, which provide the potential for priority review of a marketing application by FDA and allow for a total of ten years of market exclusivity in the event of U.S. approval. Neutrolin is already marketed as a CE Marked product in Europe and other territories. In parallel, CorMedix is leveraging its taurolidine technology to develop a pipeline of antimicrobial medical devices, with active programs in surgical sutures and meshes, and topical hydrogels.  The company is also working with top-tier researchers to develop taurolidine-based therapies for rare pediatric cancers.  For more information, visit: www.cormedix.com.

Investor Contact:

Dan Ferry

Managing Director

LifeSci Advisors

617-535-7746

Source: CorMedix, Inc.

This article appears in: News Headlines

Referenced Stocks: CRMD










Today's Market Activity

NASDAQ 7785.72
83.34  ▲  1.08%
DJIA 25877.33
197.43  ▲  0.77%
S&P 500 2864.36
24.13  ▲  0.85%
Data as of May 21, 2019